204 related articles for article (PubMed ID: 34491363)
1. Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report.
Uehara M; Nakamura Y; Nakano M; Miyazaki A; Suzuki T; Takahashi J
Mod Rheumatol Case Rep; 2022 Jan; 6(1):128-133. PubMed ID: 34491363
[TBL] [Abstract][Full Text] [Related]
2. Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta.
Dattagupta A; Petak S
AACE Clin Case Rep; 2023; 9(6):209-212. PubMed ID: 38045794
[TBL] [Abstract][Full Text] [Related]
3. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
4. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
5. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
[TBL] [Abstract][Full Text] [Related]
7. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
[TBL] [Abstract][Full Text] [Related]
8. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
9. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
[TBL] [Abstract][Full Text] [Related]
10. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
[TBL] [Abstract][Full Text] [Related]
11. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
12. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
14. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
[TBL] [Abstract][Full Text] [Related]
16. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
Lau EMC; Dinavahi R; Woo YC; Wu CH; Guan J; Maddox J; Tolman C; Yang W; Shin CS
Osteoporos Int; 2020 Apr; 31(4):677-685. PubMed ID: 32047951
[TBL] [Abstract][Full Text] [Related]
17. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
Nealy KL; Harris KB
Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
[TBL] [Abstract][Full Text] [Related]
18. Romosozumab for the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
[TBL] [Abstract][Full Text] [Related]
20. [Romosozumab : a new treatment for severe osteoporosis].
Uebelhart B; Ferrari S
Rev Med Suisse; 2021 Apr; 17(735):784-787. PubMed ID: 33881241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
